Gevokizumab is a potent anti-IL-1β antibody that negatively modulates IL-1β signaling through an allosteric mechanism; it reduces the binding affinity of IL-1β to the IL-1 receptor type I (IL-1RI) without affecting the IL-1 decoy receptor (IL-1 receptor type II).